Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scheid

Showing results (1191-1200 of 1,291) with videos related to

Pageof 130
Sort By:
Cell|February 1, 2020
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing AntibodyPhilipp Schommers, Henning Gruell, Morgan E Abernathy, et al.
Bone Marrow Transplantation|September 12, 2017
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working partyC Scheid, L de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Therapeutic Advances in Neurological Disorders|October 2, 2023
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outlineAntonios Bayas, Achim Berthele, Norbert Blank, et al.
Nature|April 10, 2015
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Marina Caskey, Florian Klein, Julio C C Lorenzi, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Nature Communications|April 9, 2025
Peripheral positioning of lysosomes supports melanoma aggressivenessKaterina Jerabkova-Roda, Marina Peralta, Kuang-Jing Huang, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Pageof 130

Showing results (1191-1200 of 1,291) with videos related to

Sort By:
Pageof 130
Cell|February 1, 2020
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing AntibodyPhilipp Schommers, Henning Gruell, Morgan E Abernathy, et al.
Bone Marrow Transplantation|September 12, 2017
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working partyC Scheid, L de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Therapeutic Advances in Neurological Disorders|October 2, 2023
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outlineAntonios Bayas, Achim Berthele, Norbert Blank, et al.
Nature|April 10, 2015
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Marina Caskey, Florian Klein, Julio C C Lorenzi, et al.
Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Frontiers in Immunology|February 19, 2021
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell MalignanciesAgnieszka Tomaszewska, Madan Jagasia, Eric Beohou, et al.
Nature Communications|April 9, 2025
Peripheral positioning of lysosomes supports melanoma aggressivenessKaterina Jerabkova-Roda, Marina Peralta, Kuang-Jing Huang, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Pageof 130